Advertisement

Mycopathologia

, Volume 181, Issue 3–4, pp 235–240 | Cite as

In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of Aspergillus Nigri Complex

  • Hamid Badali
  • Hamed Fakhim
  • Fereshteh Zarei
  • Mojtaba Nabili
  • Afsane Vaezi
  • Nafiseh Poorzad
  • Somayeh Dolatabadi
  • Hossein Mirhendi
Article

Abstract

Black aspergilli, particularly Aspergillus niger and A. tubingensis, are the most common etiological agents of otomycosis followed by onychomycosis, pulmonary aspergillosis and aspergilloma. However, so far there is no systematic study on their antifungal susceptibility profiles. A collection of 124 clinical and environmental species of black aspergilli consisted of A. niger, A. tubingensis, A. uvarum. A. acidus and A. sydowii were verified by DNA sequencing of the partial β-tubulin gene. MICs of amphotericin B, itraconazole, voriconazole, posaconazole, and MECs of caspofungin were performed based on CLSI M38-A2. Posaconazole and caspofungin had the lowest MIC range (0.016–0.125 µg/ml and 0.008–0.031 µg/ml, respectively), followed by amphotericin B (0.25–4 µg/ml), voriconazole (0.125–16 µg/ml) and itraconazole (0.25 to >16) in an increasing order. Some strains of A. niger showed high MIC value for itraconazole and voriconazole (>16 µg/ml), in contrast only environmental isolates of A. tubingensis had high itraconazole MICs (>16 µg/ml). These results confirm that posaconazole and caspofungin are potential drugs for treatment of aspergillosis due to opportunistic agents of Aspergillus Nigri complex. However, in vivo efficacy remains to be determined.

Keywords

Aspergillus Nigri complex In vitro susceptibility Partial β-tubulin (BTU) 

Notes

Acknowledgments

This study was financially supported by a grant from the School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran (no. 1106) which we gratefully acknowledge. We are grateful to Iman Haghani for excellent technical assistance and help with antifungal susceptibility testing.

Compliance with Ethical Standards

Conflict of interest

The authors report no conflicts of interest.

References

  1. 1.
    Abarca ML, Accensi F, Cano J, Cabañes FJ. Taxonomy and significance of black aspergilli. Antonie Van Leeuwenhoek. 2004;86(1):33–49.CrossRefPubMedGoogle Scholar
  2. 2.
    Peterson SW. Phylogenetic analysis of Aspergillus species using DNA sequences from four loci. Mycologia. 2008;100(2):205–26.CrossRefPubMedGoogle Scholar
  3. 3.
    Perrone G, Stea G, Epifani F, Varga J, Frisvad JC, Samson RA. Aspergillus niger contains the cryptic phylogenetic species A. awamori. Fungal Biol. 2011;115(11):1138–50.CrossRefPubMedGoogle Scholar
  4. 4.
    Kaya AD, Kiraz N. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole. Mycoses. 2007;50(6):447–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Hilmioğlu-Polat S, Metin D, Inci R, Dereli T, Kılınc I, Tümbay E. Non-dermatophytic molds as agents of onychomycosis in Izmir, Turkey—a prospective study. Mycopathologia. 2005;160(2):125–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Gheith S, Saghrouni F, Bannour W, Ben Youssef Y, Khelif A, Normand AC, et al. Characteristics of invasive aspergillosis in neutropenic haematology patients (Sousse, Tunisia). Mycopathologia. 2014;177(5):281–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Hendrickx M, Beguin H, Detandt M. Genetic re-identification and antifungal susceptibility testing of Aspergillus section Nigri strains of the BCCM/IHEM collection. Mycoses. 2012;55(2):148–55.PubMedGoogle Scholar
  9. 9.
    Howard SJ, Harrison E, Bowyer P, Varga J, Denning DW. Cryptic species and azole resistance in the Aspergillus niger complex. Antimicrob Agents Chemother. 2011;55(10):4802–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zarei F, Mirhendi H, Fakhim H, Geramishoar M. The first case of onychomycosis due to Aspergillus uvarum (section Nigri). Mycoses. 2015;58(4):239–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother. 2009;53(10):4514–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 2013;9(10):e1003633.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chowdhary A, Sharma C, van den Boom M, Yntema JB, Hagen F, Verweij PE, et al. Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. J Antimicrob Chemother. 2014;69(11):2979–83.CrossRefPubMedGoogle Scholar
  14. 14.
    Badali H, Vaezi A, Haghani I, Yazdanparast SA, Hedayati MT, Mousavi B, et al. Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran. Mycoses. 2013;56(6):659–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Howard SJ. Multi-resistant aspergillosis due to cryptic species. Mycopathologia. 2014;178(5–6):435–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Samson RA, Noonim P, Meijer M, Houbraken J, Frisvad JC, Varga J. Diagnostic tools to identify black aspergilli. Stud Mycol. 2007;59:129–45.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Szigeti G, Kocsubé S, Dóczi I, Bereczki L, Vágvölgyi C, Varga J. Molecular identification and antifungal susceptibilities of black Aspergillus isolates from otomycosis cases in Hungary. Mycopathologia. 2012;174(2):143–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Zarei F, Mirhendi H, Motamedi M, Ahmadi B, Nouripour-Sisakht S, Zarrinfar H, et al. Black Aspergillus species isolated from clinical and environmental samples in Iran. J Med Microbiol. 2015;. doi: 10.1099/jmm.0.000166.PubMedGoogle Scholar
  19. 19.
    Clinical and Laboratory Standards Institute. Reference method for broth dilution antimicrobial susceptibility testing of filamentous fungi—Second Edition: Approved Standard M38–A2. Wayne: CLSI; 2008.Google Scholar
  20. 20.
    Morio F, Aubin GG, Danner-Boucher I, Haloun A, Sacchetto E, Garcia-Hermoso D, et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother. 2012;67(8):1870–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhao Y, Stensvold CR, Perlin DS, Arendrup MC. Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fluid samples of patients with chronic diseases. J Antimicrob Chemother. 2013;68(7):1497–504.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009;12(6):141–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  • Hamid Badali
    • 1
  • Hamed Fakhim
    • 2
  • Fereshteh Zarei
    • 3
  • Mojtaba Nabili
    • 2
  • Afsane Vaezi
    • 2
  • Nafiseh Poorzad
    • 2
  • Somayeh Dolatabadi
    • 4
    • 5
  • Hossein Mirhendi
    • 6
  1. 1.Department of Medical Mycology and Parasitology, School of Medicine/Invasive Fungi Research CenterMazandaran University of Medical SciencesSariIran
  2. 2.Student Research CommitteeMazandaran University of Medical SciencesSariIran
  3. 3.Department of Medical Mycology and Parasitology, School of Public HealthTehran University of Medical SciencesTehranIran
  4. 4.CBS-KNAW Fungal Biodiversity CentreUtrechtThe Netherlands
  5. 5.Cellular and Molecular Research CenterSabzevar University of Medical SciencesSabzevarIran
  6. 6.Department of Medical Parasitology and Mycology, School of MedicineIsfahan University of Medical SciencesIsfahanIran

Personalised recommendations